Sensex
80,426.46 profit arw -733.22 (-0.90%)
Nifty
24,654.70 profit arw -236.15 (-0.95%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 22-Sep-2025
Hot Pursuit
22-Sep-2025     10:09

Zydus Life receives EIR from USFDA for Ahmedabad facility

The inspection was conducted from 9th to 18th June 2025. The EIR has classified the facility as Voluntary Action Indicated (VAI). The facility was earlier classified as an Official Action Indicated (OAI) in June 2024 which is now revised to Voluntary Action Indicated (VAI).

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company's consolidated net profit rose 3.3% to Rs 1,466.80 crore on 7% rise in revenue from operations to Rs 6,467 crore in Q1 FY26 over Q1 FY25.

The counter shed 0.31% to Rs 1033.75 on the BSE.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

80,426.46 -733.22 (-0.90%)

Nifty

24,654.70 -236.15 (-0.95%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

26,128.21 -356.48(-1.35%)